It’s not just the tech billionaires descending on Washington. Plenty of chief executives from other industries are also ...

Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.

With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

The World Economic Forum’s Annual Meeting agenda promises to cover sustainability and energy issues from the environment to people and new technologies ...

Riley Wealth Management chief market strategist Art Hogan discusses whether the Fed's interest rate move changed his investment focus on 'The Claman Countdown.' Euro Pacific Capital chief economist ...

FDA Commissioner Robert Califf is closing the book on his second stint leading the agency that regulates products accounting ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Artbio, a clinical-stage radiopharmaceutical company, named Johnson & Johnson alum Margaret Yu as chief medical officer. Saisei Ventures tapped Dr. Sven Kili as partner. OSE Immunotherapeutics ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The ...

Eight years ago, Donald Trump’s inauguration smashed fundraising records and drew in high-dollar donors across the corporate ...